Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors
Purpose: To describe the results of the off-label use of eltrombopag in patients with solid tumors and thrombocytopenia that limits chemotherapy. Methods: Retrospective observational study including all patients with solid tumors who were treated with eltrombopag for thrombocytopenia during the...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2015-02-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/8580.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846093673214771200 |
|---|---|
| author | María Henar García Lagunar Pablo Cerezuela Fuentes Mónica Martínez Penella Dolores Paula Gutiérrez-Meca Maestre María García Coronel María José Martínez Ortiz |
| author_facet | María Henar García Lagunar Pablo Cerezuela Fuentes Mónica Martínez Penella Dolores Paula Gutiérrez-Meca Maestre María García Coronel María José Martínez Ortiz |
| author_sort | María Henar García Lagunar |
| collection | DOAJ |
| description | Purpose: To describe the results of the off-label use of eltrombopag in patients with solid tumors and thrombocytopenia that limits
chemotherapy. Methods: Retrospective observational study including all patients with solid tumors who were treated with eltrombopag for
thrombocytopenia during the chemotherapy treatment between January 2012 and December 2014. Results: Six patients, with solid tumors and thrombocytopenia that limits chemotherapy treatment, received eltrombopag during the study and it was observed a decrease in the delay of chemotherapy cycles (4.83 ± 4.79 delayed cycles before starting eltrombopag vs 2.50 ± 4.32 delayed cycles during the treatment with eltrombopag, p=0.492) and an increase in the percentage of administrated dosage (89.29 ± 13.36% vs 91.43 ± 10.69%, p=0.682). Also, there was an increase in platelet nadir (55.29 ± 16.45x109/L vs 76.14 ± 36.38x109/L, p=0.248) without platelet transfusion support in any patient during treatment with eltrombopag. Conclusions: eltrombopag has resulted to be an alternative in the treatment of patients with thrombocytopenia that limits chemotherapy, clinical trials with more number or patients are needed to confirm these results |
| format | Article |
| id | doaj-art-d75d4b13bc2f4342a2a157384a062e07 |
| institution | Kabale University |
| issn | 1130-6343 2171-8695 |
| language | English |
| publishDate | 2015-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Farmacia Hospitalaria |
| spelling | doaj-art-d75d4b13bc2f4342a2a157384a062e072025-01-02T16:48:59ZengElsevierFarmacia Hospitalaria1130-63432171-86952015-02-0139315716010.7399/fh.2015.39.3.8580Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumorsMaría Henar García Lagunar0Pablo Cerezuela Fuentes1Mónica Martínez Penella2Dolores Paula Gutiérrez-Meca Maestre3María García Coronel4María José Martínez Ortiz5Servicio de Farmacia. Hospital General Universitario Santa Lucía. CartagenaServicio de Oncología Médica. Hospital General Universitario Santa Lucía. Servicio de Farmacia. Hospital General Universitario Santa Lucía. CartagenaServicio de Hematología. Hospital General Universitario Santa Lucía. Cartagena. Servicio de Farmacia. Hospital General Universitario Santa Lucía. CartagenaServicio de Oncología Médica. Hospital General Universitario Santa Lucía. Purpose: To describe the results of the off-label use of eltrombopag in patients with solid tumors and thrombocytopenia that limits chemotherapy. Methods: Retrospective observational study including all patients with solid tumors who were treated with eltrombopag for thrombocytopenia during the chemotherapy treatment between January 2012 and December 2014. Results: Six patients, with solid tumors and thrombocytopenia that limits chemotherapy treatment, received eltrombopag during the study and it was observed a decrease in the delay of chemotherapy cycles (4.83 ± 4.79 delayed cycles before starting eltrombopag vs 2.50 ± 4.32 delayed cycles during the treatment with eltrombopag, p=0.492) and an increase in the percentage of administrated dosage (89.29 ± 13.36% vs 91.43 ± 10.69%, p=0.682). Also, there was an increase in platelet nadir (55.29 ± 16.45x109/L vs 76.14 ± 36.38x109/L, p=0.248) without platelet transfusion support in any patient during treatment with eltrombopag. Conclusions: eltrombopag has resulted to be an alternative in the treatment of patients with thrombocytopenia that limits chemotherapy, clinical trials with more number or patients are needed to confirm these resultshttp://www.aulamedica.es/fh/pdf/8580.pdfEltrombopagThrombocytopeniaChemotherapy;Solid tumors |
| spellingShingle | María Henar García Lagunar Pablo Cerezuela Fuentes Mónica Martínez Penella Dolores Paula Gutiérrez-Meca Maestre María García Coronel María José Martínez Ortiz Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors Farmacia Hospitalaria Eltrombopag Thrombocytopenia Chemotherapy; Solid tumors |
| title | Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors |
| title_full | Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors |
| title_fullStr | Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors |
| title_full_unstemmed | Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors |
| title_short | Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors |
| title_sort | experience of off label use of eltrombopag in the treatment of thrombocytopenia associated with solid tumors |
| topic | Eltrombopag Thrombocytopenia Chemotherapy; Solid tumors |
| url | http://www.aulamedica.es/fh/pdf/8580.pdf |
| work_keys_str_mv | AT mariahenargarcialagunar experienceofofflabeluseofeltrombopaginthetreatmentofthrombocytopeniaassociatedwithsolidtumors AT pablocerezuelafuentes experienceofofflabeluseofeltrombopaginthetreatmentofthrombocytopeniaassociatedwithsolidtumors AT monicamartinezpenella experienceofofflabeluseofeltrombopaginthetreatmentofthrombocytopeniaassociatedwithsolidtumors AT dolorespaulagutierrezmecamaestre experienceofofflabeluseofeltrombopaginthetreatmentofthrombocytopeniaassociatedwithsolidtumors AT mariagarciacoronel experienceofofflabeluseofeltrombopaginthetreatmentofthrombocytopeniaassociatedwithsolidtumors AT mariajosemartinezortiz experienceofofflabeluseofeltrombopaginthetreatmentofthrombocytopeniaassociatedwithsolidtumors |